{
    "id": 19430,
    "cites": 92,
    "cited_by": 5,
    "reference": [
        "Abramowicz, Michael, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The danger of underdeveloped patent prospects,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Cornell Law Review, 2007, 92, 1065\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1121.",
        "Abrams, David, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Did TRIPS spur innovation? An analysis of patent duration and incentives to innovate, \u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d University of Pennsylvania Law Review, 2009, 157 (6), 1613\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1647.",
        "Acemoglu, Daron and Joshua Linn, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market size in innovation: Theory and evidence from the pharmaceutical industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics, 2004, 119, 1049\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1090.",
        "Adams, Christopher and Van Brantner, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Estimating the cost of new drug development: Is it really $802 million?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health A\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00acairs, 2006, 25 (2), 420\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c428.",
        "Agha, Leila and David Molitor, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Technology adoption under uncertainty: O\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00ac-label prescribing in cancer care,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d mimeo, Boston University 2012.",
        "Allison, Malorye, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Reinventing clinical trials,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Nature Biotechnology, 2012, 30 (1), 41\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c49.",
        "American Society for Clinical Oncology, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Accelerating Progress Against Cancer: ASCO\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Blueprint for Transforming Clinical and Translational Cancer Research,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d http://www.asco.org/ASCOv2/ Department%20Content/Cancer%20Policy%20and%20Clinical%20Affairs/Downloads/Blueprint. pdf 2011.",
        "Angrist, Joshua and Jorn-Ste\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00acen Pischke, Mostly Harmless Econometrics: An Empiricist\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Companion, Princeton University Press, 2009.",
        "Bartfai, Tamas and Graham Lees, Drug Discovery: From Bedside to Wall Street, Academic Press, 2006.",
        "Bloom, Nick, Mark Schankerman, and John Van Reenen, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Identifying technology spillovers and product market rivalry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Econometrica, 2013, 81, 1347\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1393.",
        "Bronnenberg, Bart, Jean-Pierre Dube, Matthew Gentzkow, and Jesse Shapiro, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Do pharmacists buy Bayer? Sophisticated shoppers and the brand premium,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d mimeo, Chicago Booth 2013.",
        "Chin, Richard and Menghis Bairu, eds, Global Clinical Trials: E\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00acective Implementation and Management, Academic Press, 2011.",
        "Cohen, Wesley, Richard Nelson, and John Walsh, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Protecting their intellectual assets: Appropriability conditions and why US manufacturing \u00c3\u00af\u00c2\u00ac\u00c2\u0081rms patent (or not),\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Bureau of Economic Research (NBER) working paper 7552 2000.",
        "Collett, David, Modelling Survival Data in Medical Research, Second Edition, Chapman and Hall/CRC, 2003.",
        "Collins, Francis, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Testimony before the US House Subcommittee on Labor - HHS - Education Appropriations, \u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Department of Health and Human Services, National Institutes of Health 2012.",
        "Cutler, David, Your Money or Your Life: Strong Medicine for America\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Health Care System, Oxford University Press, 2004.",
        "Datamonitor Group, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093US most susceptible to brand erosion post patent expiry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Datamonitor Press Release http://about.datamonitor.com/media/archives/5293 2011.",
        "de Bono, Johann, Christopher Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim Chi, Robert Jones, Oscar Goodman, Fred Saad, John Sta\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00acurth, Paul Mainwaring, Stephen Harland, Thomas Flaig, Thomas Hutson, Tina Cheng, Helen Patterson, John Hainsworth, Charles Ryan, Cora Sternberg, Susan Ellard, Aude Fl\u00c3\u0083\u00c2\u00a9chon, Mansoor Saleh, Mark Scholz, Eleni Efstathiou, Andrea Zivi, Diletta Bianchini, Yohann Loriot, Nicole Chie\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00aco, Thian Kheoh, Christopher Haqq, and Howard I. Scher, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Abiraterone and increased survival in metastatic prostate cancer,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine, 2011, 364 (21), 1995\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2005.",
        "DiMasi, Joseph, Ronald Hansen, and Henry Grabowski, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The price of innovation: New estimates of drug development costs,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics, 2003, 22, 151\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c185.",
        "Dubois, Pierre, Fiona Scott Morton, Paul Seabright, and Olivier de Mouzon, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market size and pharmaceutical innovation,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d mimeo, Toulouse School of Economics 2012.",
        "Editorial Board, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drugs for early-stage Alzheimer\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New York Times, 2013, 17 March.",
        "Eisenberg, Rebecca, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The problem of new uses,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Yale Journal of Health Policy, Law, & Ethics, 2005, 717.",
        "Farber, Sidney, Louis Diamond, Robert Mercer, Robert Sylvester, and James Wol\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00ac, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin),\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine, 1948, 238 (23), 787\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c793.",
        "Finkelstein, Amy, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Static and dynamic e\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00acects of health policy: Evidence from the vaccine industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics, 2004, 119, 527\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c564.",
        "Fisher, Bernard, Joseph Costantino, D. Lawrence Wickerham, Carol Redmond, Maureen Kavanah, Walter Cronin, Victor Vogel, Andre Robidoux, Nikolay Dimitrov, James Atkins, Mary Daly, Samuel Wieand, Elizabeth Tan-Chiu, Leslie Ford, Norman Wolmark, other National Surgical Adjuvant Breast, and Bowel Project Investigators, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of the National Cancer Institute, 1998, 90 (18), 1371\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1388.",
        "Fleming, Thomas, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Surrogate endpoints and FDA\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s accelerated approval process,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health A\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00acairs, 2005, 24, 67\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c78.",
        "Galli, Bruno and Bernard Faller, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Discover a drug substance, formulate and develop it to a product,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in Camille Georges Wermuth, ed., The Practice of Medicinal Chemistry, 2 ed. 2003, pp. 857\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c866.",
        "Gilbert, Richard and Carl Shapiro, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Optimal patent length and breadth,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics, 1990, 21, 106\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c112.",
        "Go\u00c3\u00af\u00c2\u00ac\u00c6\u0092n, John, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Introduction to clinical trials,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in Shayne Cox Gad, ed., Clinical Trials Handbook, Wiley, 2009, pp. 1\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c22.",
        "Grabowski, Henry and Margaret Kyle, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Generic competition and market exclusivity periods in pharmaceuticals,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Managerial and Decision Economics, 2007, 28 (4-5), 491\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c502.",
        "Grossman, Gene and Edwin Lai, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093International protection of intellectual property,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review, 2004, 94, 1635\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1653.",
        "Hammitt, James and Kevin Haninger, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Valuing fatal risks to children and adults: E\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00acects of disease, latency, and risk aversion,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Risk and Uncertainty, 2010, 40 (1), 57\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c83.",
        "Hemphill, C Scott and Bhaven Sampat, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Evergreening, patent challenges, and e\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00acective market life in pharmaceuticals,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics, 2011, 31 (2), 327\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c339.",
        "Hovde, Mark, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Chapter 7: Management of clinical development costs,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in Chi-Jen Lee, Lucia Lee, Christopher Wu, Benjamin Lee, and Mei-Ling Chen, eds., Clinical Trials of Drugs and Biopharmaceuticals, CRC Press, 2006, chapter 7, pp. 97\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c102.",
        "Johnson, John, Grant Williams, and Richard Pazdur, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093End points and United States Food and Drug Administration approval of oncology drugs,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Clinical Oncology, 2003, 21, 1404\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1411.",
        "Jones, Christopher, Daniel Hunt, David McGowan, Mahul Amin, Michael Chetner, Deborah Bruner, Mark Leibenhaut, Siraj Husain, Marvin Rotman, Luis Souhami, Howard Sandler, and William Shipley, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Radiotherapy and short-term androgen deprivation for localized prostate cancer,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine, 2011, 365 (2), 107\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c118.",
        "Kaplow, Louis, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The patent-antitrust intersection: A reappraisal,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Harvard Law Review, 1984, 97, 1815\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 1892.",
        "Kitch, Edmund, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The nature and function of the patent system,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and Economics, 1977, 20, 265\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c290.",
        "Klemperer, Paul, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093How broad should the scope of patent protection be?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics, 1990, 21, 113\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c130.",
        "Kohan, Donald, John Cleland, Dan Theodorecsuc, Lewis Rubin, and Matthias Barton, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Life Sciences, 2012.",
        "Korn, David and Donald Stanski, Drug Development Science: Obstacles and Opportunities for Collaboration Among Academia, Industry and Government, Association of American Medical Colleges, 2005.",
        "Kozauer, Nicholas and Russell Katz, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Regulatory innovation and drug development for early-stage Alzheimer\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s disease,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine, 2013, e-publication ahead of print.",
        "Kremer, Michael, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patent buyouts: A mechanism for encouraging innovation,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Quarterly Journal of Economics, 1998, 113 (4), 1137\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1167.",
        "Lakdawalla, Darius, Eric Sun, Anupam Jena, Carolina Reyes, Dana Goldman, and Tomas Philipson, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093An economic evaluation of the war on cancer,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics, 2010, 29 (3), 333\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c346.",
        "Lamm, Donald, Brent Blumenstein, E. David Crawford, James Montie, Peter Scardino, H. Barton Grossman, Thomas Stanisic, Joseph Smith, Jerry Sullivan, Michael Sarosdy, John Crissman, and Charles Coltman, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A randomized trial of intravesical doxorubicin and immunotherapy with bacille calmette-guerin for transitional-cell carcinoma of the bladder,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine, 1991, 325 (17), 1205\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1209.",
        "Lathia, CD, D Amakye, W Dai, C Girman, S Madani, J Mayne, P MacCarthy, P Pertel, L Seman, A Stoch, P Tarantino, C Webster, S Williams, and JA Wagner, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The value, quali\u00c3\u00af\u00c2\u00ac\u00c2\u0081cation, and regulatory use of surrogate end points in drug development,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Clinical Pharmacology & Therapeutics, 2009, 86 (1), 32\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c43.",
        "Lee, Benjamin, Chi-Jen Lee, Christpher Wu, and Lucia Lee, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Decision points in drug development, \u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in Chi-Jen Lee, Lucia Lee, Christopher Wu, Benjamin Lee, and Mei-Ling Chen, eds., Clinical Trials of Drugs and Biopharmaceuticals, CRC Press, 2006, chapter 6, pp. 77\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c86.",
        "Lerner, Josh, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patent protection and innovation over 150 years,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Bureau of Economic Research (NBER) working paper 8977 2002.",
        "Leveque, Dominique, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093O\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00ac-label use of anticancer drugs,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Lancet Oncology, 2008, 9, 1102\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1107.",
        "Levin, Richard, Alvin Klevorick, Richard Nelson, Sidney Winter, Richard Gilbert, and Zvi Griliches, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Appropriating the returns from industrial research and development,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Brookings Papers on Economic Activity, 1987, 1987 (3), 783\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c831.",
        "Lichtenberg, Frank, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The e\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00acect of pharmaceutical innovation on longevity: Patient-level evidence from the 1996-2002 Medical Expenditure Panel Survey and linked mortality public-use \u00c3\u00af\u00c2\u00ac\u00c2\u0081les,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Bureau of Economic Research (NBER) working paper 18552 2012.",
        "Lindgren, Peter and Bengt Jonsson, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Cost-e\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00acectiveness of statins revisited: Lessons learned about the value of innovation,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d European Journal of Health Economics, 2012, 13 (4), 445\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c450.",
        "Lippman, Scott and Ernest Hawk, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Cancer prevention: From 1727 to milestones of the past 100 years,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Cancer Research, 2009, 69, 5269.",
        "Machlup, Fritz, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093An economic review of the patent system,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Study of the Subcommittee on Patents, Trademarks, and Copyrights of the Committee on the Judiciary, United States Senate, 85th Congress, Second Session 1958.",
        "Malani, Anup and Tomas Philipson, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Can medical progress be sustained? Implications of the link between development and output markets,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Bureau of Economic Research (NBER) working paper 17011 2011.",
        "Mans\u00c3\u00af\u00c2\u00ac\u00c2\u0081eld, Edwin, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patents and innovation: An empirical study,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Management Science, 1986, 32, 173\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 181.",
        ", Mark Schwartz, and Samuel Wagner, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Imitation costs and patents: An empirical study,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Economic Journal, 1981, 91 (364), 907\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c918.",
        "Mayer Brown, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pharma & biotech - drug development: Valuing the pipeline: A UK study,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d http://www.mayerbrown.com/files/Publication/53189dc5-d8f8-45aa-9d4d-62646b17c2e8/ Presentation/PublicationAttachment/c7199cda-f73d-4377-a09d-cc26afc93408/0728ten_ Valuation_Report.pdf 2009.",
        "Mcintyre, William, Michael Downs, and Sondra Bedwell, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Treatment options for actinic keratoses, \u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Family Physician, 2007, 76 (5), 667\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c671.",
        "Meyskens, Frank, Gregory Curt, Dean Brenner, Gary Gordon, Ronald Herberman, Olivera Finn, Gary Kello\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00ac, Samir Khleif, Caroline Sigman, and Eva Szabo, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Regulatory approval of cancer risk-reducing (chemopreventive) drugs: Moving what we have learned into the clinic,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Cancer Prevention Research, 2011, 4 (3), 311\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c323.",
        "Moser, Petra, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093How do patent laws in\u00c3\u00af\u00c2\u00ac\u00e2\u0080\u009auence innovation? Evidence from nineteenth-century world fairs,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review, 2005, 95, 1214\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1236.",
        "Mossingho\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00ac, Gerald, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Overview of the Hatch-Waxman Act and its impact on the drug development process,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Food & Drug Law Journal, 1999, 54 (2), 187\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c194.",
        "Mukherjee, Siddhartha, The Emperor of All Maladies: A Biography of Cancer, New York, NY: Scribner, 2010.",
        "Murphy, Kevin and Robert Topel, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The value of health and longevity,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy, 2006, 114, 871\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c904.",
        "Nordhaus, William, Invention, Growth, and Welfare: A Theoretical Treatment of Technological Change, Cambridge, MA: MIT Press, 1969.",
        ", \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The optimum life of a patent: Reply,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review, 1972, 62 (3), 428\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c431.",
        ", \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Schumpeterian pro\u00c3\u00af\u00c2\u00ac\u00c2\u0081ts in the American economy: Theory and measurement,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Bureau of Economic Research (NBER) working paper 10433 2004.",
        "Patrick, Graham, An Introduction to Medicinal Chemistry, 2 ed., Oxford University Press Oxford, 2005.",
        "Pazdur, Richard, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Response rates, survival, and chemotherapy trials,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of the National Cancer Institute, 2000, 92 (19), 1552\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1553.",
        "Philipson, Tomas and Anupam Jena, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Who bene\u00c3\u00af\u00c2\u00ac\u00c2\u0081ts from new medical technologies? Estimates of consumer and producer surpluses for HIV/AIDS drugs,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Forum for Health Economics & Policy, 2006, 9 (2).",
        ", Gary Becker, Dana Goldman, and Kevin Murphy, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Terminal care and the value of life near its end,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Bureau of Economic Research (NBER) working paper 15649 2010.",
        "Public Law Number 111-148, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patient Protection and A\u00c3\u00af\u00c2\u00ac\u00e2\u0082\u00acordable Care Act,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 124 Stat. 119 2010.",
        "Public Law Number 98-417, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drug Price Competition and Patent Term Restoration Act (\u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093HatchWaxman \u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d) Act of 1984,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 98 Stat. 1585 1984.",
        "Roin, Benjamin, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drug patent length,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d mimeo, Harvard Law School 2010.",
        "Sakakibara, Mariko and Lee Branstetter, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Do stronger patents induce more innovation? Evidence from the 1998 Japanese patent law reforms,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics, 2001, 32 (1), 77\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c100.",
        "Schankerman, Mark and Ariel Pakes, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Estimates of the Value of Patent Rights in European Countries During the Post-1950 Period,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Economic Journal, 1986, 96 (384), 1052\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1076.",
        "Scherer, F.M., \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Nordhaus\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 theory of optimal patent life: A geometric reinterpretation,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review, 1972, 62, 422\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c427.",
        "Schmookler, Jacob, Invention and Economic Growth, Cambridge, MA: Harvard University Press, 1966.",
        "Schreiner, Stephen and Patrick Doody, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patent continuation applications: How the PTO\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s proposed new rules undermine an important part of the US patent system with hundreds of years of history,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of the Patent and Trademark O\u00c3\u00af\u00c2\u00ac\u00c6\u0092ce Society, 2006, 88, 556\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c569.",
        "Scotchmer, Suzanne, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Standing on the shoulders of giants: Cumulative research and the patent law,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Perspectives, 1991, 5, 29\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c41.",
        "Stein, Jeremy, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093E\u00c3\u00af\u00c2\u00ac\u00c6\u0092cient capital markets, ine\u00c3\u00af\u00c2\u00ac\u00c6\u0092cient \u00c3\u00af\u00c2\u00ac\u00c2\u0081rms: A model of myopic corporate behavior,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics, 1989, 104, 655\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c669.",
        ", \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Agency, information, and corporate investment,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Handbook of the Economics of Finance,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Elsevier, 2003, chapter 2.",
        "Thomas, Gareth, Fundamentals of Medicinal Chemistry, John Wiley & Sons, Ltd, 2003.",
        ", Medicinal Chemistry: An Introduction, Wiley-Interscience, 2007.",
        "Trusheim, Mark and Ernst Berndt, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The segmentation of therapeutic populations in oncology,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d mimeo, MIT 2012.",
        "US Food and Drug Administration, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Guidance for industry: Clinical trial endpoints for the approval of cancer drugs and biologics,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf 2007.",
        "US Institute of Medicine, Improving the quality of cancer clinical trials: Workshop summary, The National Academies Press, 2008.",
        "Wegner, Harold and Stephen Maebius, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The global biotech patent application,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Biotechnology Law: Biotechnology Patents& Business Strategies in the New Millennium\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Intellectual property course handbook, Practising Law Institute, 2001, pp. 129\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c130.",
        "Weitzman, Martin, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Why the far-distant future should be discounted at its lowest possible rate,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Environmental Economics and Management, 1998, 36 (3), 201\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c208.",
        "Welch, H. Gilbert, Lisa Schwartz, and Steven Woloshin, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Are increasing 5-year survival rates evidence of success against cancer?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of the American Medical Association, 2000, 283 (22), 2975\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2978.",
        "Weyl, Glen and Jean Tirole, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market power screens willingness-to-pay,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics, 2012, 127, 1971\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2003.",
        "Wroblewski, Michael, Elizabeth Jex, Suzanne Drennon Munck, Christopher Garmon, Suzanne Michel, Alissa Wantman, and Ossie Neal, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Emerging health care issues: Follow-on biological drug competition,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Federal Trade Commission Report http://www.ftc.gov/os/2009/06/ P083901biologicsreport.pdf 2009."
    ]
}